Kyverna Therapeutics Inc

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors In KYTX Have The Chance To Participate In The Securities Fraud Probe Against Kyverna Therapeutics, Inc. With The Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm.

KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Promising results from early clinical experience with anti-CD19 CAR T cells in patients with autoimmune diseases Optimal CAR construct design contributing to an acceptable safety profile, and potential for lasting immune reset are key for treatment adoption  Kyverna is currently recruiting for multiple KYSA trials where the company's product candidate KYV-101 is used to treat patients suffering from myasthenia gravis, multiple sclerosis, and lupus nephritis EMERYVILLE, Calif. , June 10, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled "Chimeric antigen receptor T cell therapy for autoimmune disease"1.

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology

Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology Treated 30 patients cumulatively as of May 14, 2024, including eight patients with myasthenia gravis, seven patients with lupus nephritis, and four patients with multiple sclerosis Strong balance sheet, bolstered by recent public offering EMERYVILLE, Calif. , May 14, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2024.

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells Kyverna to host a conference call on April 16 to review recent named-patient experience in patients suffering from multiple sclerosis and myasthenia gravis EMERYVILLE, Calif. , April 11, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today its attendance at the 2024 annual meeting of the American Academy of Neurology to be held in Denver, Colorado, starting on April 13.

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies The treatment resulted in an acceptable safety profile, with no observed clinical signs of early neurotoxicity, warranting larger clinical studies in subjects with multiple sclerosis EMERYVILLE, Calif. , March 29, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announces today the publication in Med1, of a report describing the first use of KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, in two patients suffering from progressive multiple sclerosis (MS) as part of a named patient program for critically ill patients after both patients failed to respond to conventional therapies.

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology Strong balance sheet, bolstered by recent public offering, expected to fund operations into 2026 EMERYVILLE, Calif. , March 26, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the full year ended December 31, 2023.

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participants The clinical study will be supported by cutting edge correlative studies funded through a parallel research collaboration between Kyverna and Stanford University The agreements further expand the scale of ongoing clinical studies assessing the potential therapeutic effects of KYV-101 in multiple diseases and locations around the world EMERYVILLE, Calif. , March 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the signature of a collaboration agreement with Stanford University to allow the use of KYV-101, an investigational, anti-CD19 CAR T-cell therapy in an open label, phase 1 investigator-initiated trial (IIT) in nine to twelve adult subjects with non-relapsing and progressive forms of multiple sclerosis.

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

CG oncology Inc

Biotech businesses tend to be volatile after their initial public offerings. Kyverna Therapeutics raised more than twice what was initially expected.

Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?

EMERYVILLE, Calif. , Feb. 12, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the closing of its upsized initial public offering of 16,675,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,175,000 additional shares, at an initial public offering price of $22.00 per share.

Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: Autoimmune Biotech Kyverna Therapeutics Gains 37% In A Six IPO Week

Gilead Sciences

Shares of Kyverna Therapeutics jumped 55.7% in their market debut on Thursday, giving the biopharmaceutical company that is backed by Gilead Sciences a market capitalization of $1.4 billion.

Gilead-backed Kyverna Therapeutics valued at $1.4 bln in stellar debut

Gilead-backed Kyverna Therapeutics on Wednesday said it will raise $319 million at a valuation of $898.1 million in an upsized U.S. initial public offering (IPO).

Kyverna Therapeutics to raise $319 million in upsized IPO

EMERYVILLE, Calif. , Feb. 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the pricing of its upsized initial public offering of 14,500,000 shares of its common stock at an initial public offering price of $22.00 per share.

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

Kyverna Therapeutics expects up to $857.3 million valuation in its U.S. initial public offering (IPO), the biotechnology company said on Tuesday as it raised its offering.

Gilead-backed Kyverna Therapeutics aims for $857.3 mln valuation in upsized IPO

Amer Sports Inc

American Healthcare REIT Inc

Alto Neuroscience Inc

Fibrobiologics Inc

Flutter Entertainment PLC

Fractyl Health Inc

Perfect Moment Ltd

BBB Foods Inc

Sports equipment and apparel maker Amer Sports priced below the range to raise $1.3 billion at a $6.4 billion market cap. CNS disorder biotech Alto Neuroscience priced its upsized IPO at the top of the range to raise $129 million at a $456 million market cap.

U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings

Biotechnology company Kyverna Therapeutics said on Thursday it was aiming for a market valuation of up to $711 million in its U.S. initial public offering (IPO).

Kyverna Therapeutics targets up to $711 mln valuation in US IPO

BrightSpring Health Services Inc

CCSC Technology International Holdings Ltd

JVSPAC Acquisition Corp

Two foreign issuers listed in the US this past week, joined by one blank check. Four IPOs joined the pipeline, as well as one SPAC. JVSPAC Acquisition raised $50 million in the year's first blank check IPO. The SPAC plans to target business at the intersection of lifestyle and technology. More sizable issuers are lining up for January IPOs, with two currently scheduled for the week ahead.

U.S. IPO Weekly Recap: Kaspi.Kz Completes Billion-Dollar U.S. Listing As More Big Names Join The Pipeline

Kyverna Therapeutics has filed for a $100 million IPO to develop gene-based treatments and CAR T-cell treatments for autoimmune diseases. The company's lead program, KYV-101 Neurology, is in Phase 2 trials for myasthenia gravis and multiple sclerosis. The global market for multiple sclerosis treatments is expected to reach $34.4 billion by 2030, driving the company's growth potential.

Kyverna Therapeutics Starts $100 Million IPO Effort

News for Kyverna Therapeutics Inc Stock (KYTX)